Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...
Lawrence Eichenfield, MD, outlines a patient-centered approach to atopic dermatitis, assessing disease history, life impact, and prior therapy use.
A Maui Derm 2026 session explored advancements in pediatric dermatology, emphasizing precision medicine and targeted therapies for children.
Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of ...
Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology ...
Zacks Investment Research on MSN
Corvus Pharmaceuticals stock rallies 209% in a month: Here's why
Shares of Corvus Pharmaceuticals CRVS have skyrocketed 208.8% in a month. The massive stock price rally was observed after ...
Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.
On January 23, 2026, Sanofi reported new phase 3 data showing that its investigational monoclonal antibody amlitelimab, which targets OX40-ligand without depleting T cells, delivered a strong efficacy ...
Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...
Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced ...
Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results